查菲埃立克體IgG免疫熒光玻片試劑盒

Ehrlichia chaffeensis IgG 120-test IFA Kit

廣州健侖生物科技有限公司

主要用途：用于檢測人血清中的查菲埃立克體 IgG 抗體

產品規(guī)格：12 孔/張,10 張/盒

包括包柔氏螺旋體菌、布魯氏菌、貝納特氏立克次體、土倫桿菌、鉤端螺旋體、新型立克次體、恙蟲病、立克次體、果氏巴貝西蟲、馬焦蟲、牛焦蟲、利什曼蟲、新包蟲、弓形蟲、貓流感病毒、貓冠狀病毒、貓皰疹病毒、犬瘟病毒、犬細小病毒等病原微生物的 IFA、MIF、ELISA試劑。

查菲埃立克體IgG免疫熒光玻片試劑盒

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化】

研究還發(fā)現(xiàn)，這種抗體能夠遏制胰腺癌、肺癌、抗原抗體癌、大腸癌、前列腺癌等癌細胞增殖。
研究人員指出，血液中的抗體與核糖體蛋白L29結合后，能夠遏制后者的功能，使癌細胞難以分裂，從而凋亡，因此這種抗體應該就是構成人體內腫瘤免疫系統(tǒng)的物質之一。目前他們正在研發(fā)以這種抗體為基礎的抗癌藥物和疫苗。
道格拉斯·梅爾頓比任何人都急于得到糖尿病的治愈方法，因為他的兒子在還是個嬰兒的時候就患有此病了，而他的女兒在14歲時被診斷出該病。在過去20年中的大多數時間，哈佛干細胞研究所的發(fā)育生物學家道格拉斯·梅爾頓一直將他的研究致力于該病的治愈方法的發(fā)現(xiàn)。他和他的同事在本周報告了接近這個目標的重要的一步：一個配方可以把人類干細胞轉變?yōu)楣δ苄砸葝uβ細胞——該細胞可被1型糖尿病患者(如梅爾頓的兒子和女兒)自身的免疫系統(tǒng)破壞。研究人員在本研究中轉變出的胰島β細胞通過產生胰島素對葡萄糖作出反應，如同正常β細胞所做的。當將糖尿病的形式注入到小鼠中，該細胞可以治愈這個疾病。
“糖尿病研究界為這種類型的突破已經等了好長一段時間，” 倫敦帝國學院研究β細胞遺傳的豪爾赫·費雷爾說。這個實驗室生成的細胞可能會成為用于研究糖尿病的一種有價值的工具，并且梅爾頓希望，其zui終可以用來治療患者。

The study also found that this antibody can curb pancreatic cancer, lung cancer, antigen-antibody cancer, colorectal cancer, prostate cancer and other cancer cell proliferation.
The researchers pointed out that the blood of antibodies and ribosomal protein L29 binding, the ability to contain the latter, so that cancer cells are difficult to divide, and thus apoptosis, so this antibody should constitute one of the body's tumor immune system substances. They are currently developing anti-cancer drugs and vaccines based on this antibody.
Douglas Melton is more eager than anyone to get a cure for diabetes because his son was ill when he was still a baby and his daughter was diagnosed at the age of 14. For most of the past two decades Douglas Melton, a developmental biologist at the Harvard Stem Cell Institute, has been devoting his research to the discovery of a cure for the disease. This week, he and his colleagues reported an important step closer to achieving this goal: a formula that converts human stem cells into functional islet beta cells that can be activated by type 1 diabetics (such as Melton's son and daughter Own immune system damage. The islet beta cells that the researchers transformed in this study respond to glucose by producing insulin, as does normal beta cells. When a form of diabetes is injected into mice, the cell can heal the disease.
"The diabetes community has waited for this type of breakthrough for a long time," said Jorge Ferrer, who studies beta-cell inheritance at Imperial College London. The lab-generated cells may be a valuable tool for studying diabetes and Melton hopes it can eventually be used to treat patients.